PT Phapros TbkISX:PEHA +0.78%74 ROE % is 1.48% as of Mar. 2026, which is 78% below its 10-year median of 6.72. GuruFocus rates ISX:PEHA with a GF Score™ of 74/100 and a GF Value™ of Rp385.70 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 933 Drug Manufacturers companies, PT Phapros Tbk ranks better than 61.09% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. PT Phapros Tbk's annualized net income for the quarter that ended in Mar. 2026 was Rp6,129 Mil. PT Phapros Tbk's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was Rp415,286 Mil. Therefore, PT Phapros Tbk's annualized ROE % for the quarter that ended in Mar. 2026 was 1.48%.
The historical rank and industry rank for PT Phapros Tbk's ROE % or its related term are showing as below:
ISX:PEHA'
s ROE % Range Over the Past 10 Years
Min: -54.97 Med: 6.72 Max: 18.93
Current: 8.93
During the past 13 years, PT Phapros Tbk's highest ROE % was 18.93%. The lowest was -54.97%. And the median was 6.72%.
ISX:PEHA's ROE % is ranked better than 61.09% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs ISX:PEHA: 8.93
PT Phapros Tbk (ISX:PEHA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
PT Phapros Tbk ROE % Related Terms
PT Phapros Tbk ROE % Historical Data
* Premium members only.
The historical data trend for PT Phapros Tbk's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's ROE % distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
PT Phapros Tbk (ISX:PEHA) has a ROE % of 1.48% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Phapros Tbk and its competitors. This is 78% below median its historical median of 6.72. According to the industry distribution chart, PT Phapros Tbk ranks #363 out of 933 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is PT Phapros Tbk's ROE % too high?
PT Phapros Tbk's current ROE % of 1.48% is 78% below median its 10-year median of 6.72. The Drug Manufacturers industry median ROE % is 5.89. PT Phapros Tbk's value of 1.48% is 74.9% below this industry median. Based on the distribution chart, PT Phapros Tbk ranks #363 out of 933 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Phapros Tbk has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #363 out of 933 companies for ROE %. This puts PT Phapros Tbk in the upper half of its industry. The industry median ROE % is 5.89. PT Phapros Tbk's value of 1.48% is 74.9% below this benchmark. While the company's 10-year median is 6.72 vs. the industry median of 5.89, PT Phapros Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current ROE % of 1.48% is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Phapros Tbk and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current ROE % is 1.48%, which is 78% below median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp385.70, compared to a current price of Rp260.00 — trading 32.6% below its estimated fair value. The current ROE % is 1.48%, which is 78% below median its 10-year median of 6.72 and 74.9% below the Drug Manufacturers industry median of 5.89. PT Phapros Tbk's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current ROE % is 1.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp260.00 is trading 32.6% below its estimated GF Value™ of Rp385.70.
GuruFocus considers PT Phapros Tbk to be Possible Value Trap.
Key valuation signals for ISX:PEHA:
ROE %: 1.48% (78% below median its 10-year median of 6.72)
GF Value™: Rp385.70 vs. price of Rp260.00 (32.6% below fair value)
Industry Position: 74.9% below the Drug Manufacturers median (#363 of 933)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
74GF Score
Get the complete analysis for ISX:PEHA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
